All In Biotech

Drug Trial Radar · NCT07413939

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

650

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

May 1, 2029

Study completion Sep 29, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • RO7771950Drug

    Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).

  • TucatinibDrug

    Participants will receive a dose of tucatinib PO BID.

  • TrastuzumabDrug

    Participants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC).

  • CapecitabineDrug

    Participants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR)Time frame: Approximately 35 months

Locations

219 sites in 26 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Banner Health MD Anderson AZ

    Gilbert, Arizona · Recruiting

  • Community Cancer Institute (CCI)

    Clovis, California · Recruiting

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCSF Helen Diller Family CCC

    San Francisco, California · Recruiting

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut · Recruiting

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey · Recruiting

  • New York Oncology Hematology, P.C.

    Albany, New York · Recruiting

  • New York Cancer and Blood Specialists

    Shirley, New York · Recruiting

  • Stony Brook Univ Cancer Ctr

    Stony Brook, New York · Recruiting

  • Montefiore Einstein Cancer Center

    The Bronx, New York · Recruiting

  • The West Clinic, PC dba West Cancer Center

    Germantown, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology Elliston Place Plaza

    Nashville, Tennessee · Recruiting

  • Texas Oncology Cancer Center

    Austin, Texas · Recruiting

  • The Center for Cancer and Blood Disorders - Fort Worth

    Fort Worth, Texas · Recruiting

  • Centro Médico Fleischer

    Buenos Aires, Argentina · Recruiting

  • Investigaciones Clínicas Moleculares

    Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Fundación Respirar

    CABA, Argentina · Recruiting

  • Hospital Provincial del Centenario

    Rosario, Argentina · Recruiting

  • Centro Oncológico de Excelencia

    San Juan, Argentina · Recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Barwon Health

    Geelong, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Sunshine Hospital

    St Albans, Victoria, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, Australia · Recruiting

  • Lkh-Univ. Klinikum Graz

    Graz, Austria · Recruiting

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria · Recruiting

  • Lkh Salzburg - Univ. Klinikum Salzburg

    Salzburg, Austria · Recruiting

  • Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • Cliniques Universitaires St-Luc

    Brussels, Belgium · Recruiting

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium · Recruiting

  • AZ Groeninge

    Kortrijk, Belgium · Recruiting

  • UZ Leuven Gasthuisberg

    Leuven, Belgium · Recruiting

  • AZ St Maarten Campus Leopoldstr

    Mechelen, Belgium · Recruiting

Showing 40 of 219 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.